High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival.

Q2 Medicine

BMC Clinical Pathology Pub Date : 2017-04-27 eCollection Date: 2017-01-01 DOI:10.1186/s12907-017-0047-y

Baongoc Nasri, Mikito Inokuchi, Toshiaki Ishikawa, Hiroyuki Uetake, Yoko Takagi, Sho Otsuki, Kazuyuki Kojima, Tatsuyuki Kawano

{"title":"High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival.","authors":"Baongoc Nasri, Mikito Inokuchi, Toshiaki Ishikawa, Hiroyuki Uetake, Yoko Takagi, Sho Otsuki, Kazuyuki Kojima, Tatsuyuki Kawano","doi":"10.1186/s12907-017-0047-y","DOIUrl":null,"url":null,"abstract":"Background: As the major subfamily of receptor tyrosine, erythropoietin-producing hepatocellular (Eph) receptor has been related to progression and prognosis in different types of tumors. However, the role and mechanism of EPHA3 in gastric cancer is still not well understood.Methods: Specimen were collected from 202 patients who underwent gastric resection for gastric adenocarcinoma. The expression of EphA3 was studied using immunohistochemistry. We analyzed the clinicopathological factors and prognostic relevance of EphA3 expression in gastric cancer.Results: High expression of EphA3 was associated with male predominance (p = 0.031), differentiated histology (p < 0.001), depth of tumor (p = 0.002), lymph node metastasis (p = 0.001), distant metastasis (p = 0.021), liver metastasis (p = 0.024), advanced stage (p < 0.001), and high HER2 expression (p = 0.017). Relapse-free survival (RFS) was significantly worse in patients with high expression of EphA3 than in those with low expression of EphA3 (p = 0.014). Multivariate analysis for RFS showed that depth of tumor [hazard ratio (HR) 9.333, 95% confidence interval (CI) 2.183-39.911, p = 0.003] and lymph node metastasis [hazard ratio (HR) 5.734, 95% confidence interval (CI) 2.349-13.997, p < 0.001] were independent prognostic factors.Conclusions: These findings suggest that high expression EphA3 may participate in metastasis and worse survival.","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0047-y","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12907-017-0047-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 20

Abstract

Background: As the major subfamily of receptor tyrosine, erythropoietin-producing hepatocellular (Eph) receptor has been related to progression and prognosis in different types of tumors. However, the role and mechanism of EPHA3 in gastric cancer is still not well understood.

Methods: Specimen were collected from 202 patients who underwent gastric resection for gastric adenocarcinoma. The expression of EphA3 was studied using immunohistochemistry. We analyzed the clinicopathological factors and prognostic relevance of EphA3 expression in gastric cancer.

Results: High expression of EphA3 was associated with male predominance (p = 0.031), differentiated histology (p < 0.001), depth of tumor (p = 0.002), lymph node metastasis (p = 0.001), distant metastasis (p = 0.021), liver metastasis (p = 0.024), advanced stage (p < 0.001), and high HER2 expression (p = 0.017). Relapse-free survival (RFS) was significantly worse in patients with high expression of EphA3 than in those with low expression of EphA3 (p = 0.014). Multivariate analysis for RFS showed that depth of tumor [hazard ratio (HR) 9.333, 95% confidence interval (CI) 2.183-39.911, p = 0.003] and lymph node metastasis [hazard ratio (HR) 5.734, 95% confidence interval (CI) 2.349-13.997, p < 0.001] were independent prognostic factors.

Conclusions: These findings suggest that high expression EphA3 may participate in metastasis and worse survival.

Abstract Image

查看原文本刊更多论文

EphA3(促红细胞生成素生成肝细胞A3)在胃癌中的高表达与转移和低生存率相关。

背景:促红细胞生成素产生肝细胞(Eph)受体作为酪氨酸受体的主要亚家族，与不同类型肿瘤的进展和预后有关。然而，EPHA3在胃癌中的作用和机制尚不清楚。方法:收集202例胃腺癌切除术患者标本。免疫组化法检测EphA3的表达。我们分析胃癌中EphA3表达的临床病理因素及与预后的相关性。结果:EphA3高表达与男性优势(p = 0.031)、分化组织学(p = 0.002)、淋巴结转移(p = 0.001)、远处转移(p = 0.021)、肝转移(p = 0.024)、晚期(p = 0.017)相关。EphA3高表达患者的无复发生存期(RFS)明显低于EphA3低表达患者(p = 0.014)。RFS多因素分析显示肿瘤深度[危险比(HR) 9.333, 95%可信区间(CI) 2.183 ~ 39.911, p = 0.003]和淋巴结转移[危险比(HR) 5.734, 95%可信区间(CI) 2.349 ~ 13.997, p]。结论:高表达EphA3可能参与了肿瘤转移，生存率较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Clinical Pathology Medicine-Pathology and Forensic Medicine

CiteScore

3.30

自引率

0.00%

发文量

期刊介绍： BMC Clinical Pathology is an open access journal publishing original peer-reviewed research articles in all aspects of histopathology, haematology, clinical biochemistry, and medical microbiology (including virology, parasitology, and infection control). BMC Clinical Pathology (ISSN 1472-6890) is indexed/tracked/covered by PubMed, CAS, EMBASE, Scopus and Google Scholar.